On Sunday at the Endocrine Society's Annual Meeting in Chicago, Danish biopharmaceutical company H. Lundbeck presented a result that endocrinologists tracking Cushing's disease drug development have ...

At the recent American Association of Clinical Endocrinology annual meeting, experts shared updates on the complexities of diagnosing and managing Cushing's disease, including novel drug strategies ...

H. Lundbeck A/S (Lundbeck) today announced preliminary Phase II Part A data from its ongoing study evaluating asedebart (Lu AG13909), an anti-adrenocorticotropic hormone (ACTH) monoclonal antibody, in ...

Data show investigational atumelnant drove sustained androgen reductions while enabling lowering of glucocorticoid supplementation to ...